SG11201509729YA - Use of high dose pridopidine for treating huntington's disease - Google Patents
Use of high dose pridopidine for treating huntington's diseaseInfo
- Publication number
- SG11201509729YA SG11201509729YA SG11201509729YA SG11201509729YA SG11201509729YA SG 11201509729Y A SG11201509729Y A SG 11201509729YA SG 11201509729Y A SG11201509729Y A SG 11201509729YA SG 11201509729Y A SG11201509729Y A SG 11201509729YA SG 11201509729Y A SG11201509729Y A SG 11201509729YA
- Authority
- SG
- Singapore
- Prior art keywords
- disease
- high dose
- treating huntington
- dose pridopidine
- pridopidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361837928P | 2013-06-21 | 2013-06-21 | |
| US201361877832P | 2013-09-13 | 2013-09-13 | |
| PCT/US2014/043204 WO2014205229A1 (fr) | 2013-06-21 | 2014-06-19 | Utilisation de pridopidine à forte dose pour traiter la maladie de huntington |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509729YA true SG11201509729YA (en) | 2015-12-30 |
Family
ID=52105289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509729YA SG11201509729YA (en) | 2013-06-21 | 2014-06-19 | Use of high dose pridopidine for treating huntington's disease |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10322119B2 (fr) |
| EP (1) | EP3010506B1 (fr) |
| JP (1) | JP2016523862A (fr) |
| KR (1) | KR102316933B1 (fr) |
| CN (1) | CN105592848A (fr) |
| AU (1) | AU2014281414A1 (fr) |
| BR (1) | BR112015029918A2 (fr) |
| CA (1) | CA2913781C (fr) |
| CL (1) | CL2015003690A1 (fr) |
| DK (1) | DK3010506T3 (fr) |
| EA (1) | EA201690069A1 (fr) |
| ES (1) | ES2879631T3 (fr) |
| HK (1) | HK1221646A1 (fr) |
| HU (1) | HUE054783T2 (fr) |
| IL (1) | IL242804B (fr) |
| MX (1) | MX2015017307A (fr) |
| PE (2) | PE20170302A1 (fr) |
| PH (1) | PH12015502691A1 (fr) |
| PL (1) | PL3010506T3 (fr) |
| SG (1) | SG11201509729YA (fr) |
| TW (1) | TW201529069A (fr) |
| UA (1) | UA122999C2 (fr) |
| UY (1) | UY35624A (fr) |
| WO (1) | WO2014205229A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| EA201390332A1 (ru) | 2010-09-03 | 2013-08-30 | Ивакс Интернэшнл Гмбх | Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов |
| UY34503A (es) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| ES2911800T3 (es) * | 2014-01-22 | 2022-05-20 | Prilenia Neurotherapeutics Ltd | Formulaciones de liberación modificada de pridopidina |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (fr) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | Sel de l-tartrate de pridopidine |
| US10603311B2 (en) * | 2015-02-25 | 2020-03-31 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| WO2017015615A1 (fr) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Formulations à base de pridopidine et utilisation desdites formulations |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| CA3015512C (fr) | 2016-02-24 | 2024-01-16 | Teva Pharmaceuticals International Gmbh | Traitement d'une maladie neurodegenerative de l'oeil a l'aide de pridopidine |
| EP3503890A4 (fr) * | 2016-08-24 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | Utilisation de la pridopidine pour le traitement des dystonies |
| WO2018039477A1 (fr) * | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Utilisation de la pridopidine pour le traitement du déclin fonctionnel |
| JP2019529411A (ja) * | 2016-09-15 | 2019-10-17 | プリレニア ニューロセラピューティクス リミテッド | 不安症およびうつ病の治療のためのプリドピジンの使用 |
| CA3036984C (fr) | 2016-09-16 | 2023-07-18 | Prilenia Therapeutics Development Ltd. | Utilisation de la pridopidine pour le traitement du syndrome de rett |
| WO2018136600A1 (fr) | 2017-01-20 | 2018-07-26 | Teva Pharmaceuticals International Gmbh | Utilisation de pridopidine pour traiter le syndrome de l'x fragile |
| CA3072882C (fr) * | 2017-08-14 | 2023-03-21 | Prilenia Neurotherapeutics Ltd. | Methodes de traitement de la sclerose laterale amyotrophique avec la pridopidine |
| AU2018326596B2 (en) * | 2017-08-30 | 2021-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
| WO2019050775A1 (fr) | 2017-09-08 | 2019-03-14 | Teva Pharmaceuticals International Gmbh | Pridopidine pour le traitement de dyskinésies induites par un médicament |
| EA202193190A1 (ru) * | 2019-06-12 | 2022-03-24 | Прилиния Ньюротерапьютикс Лтд. | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов |
| JP7432711B2 (ja) * | 2019-09-17 | 2024-02-16 | エフ． ホフマン－ラ ロシュ アーゲー | 動作障害患者に対する個別化医療の改善 |
| WO2022094565A1 (fr) * | 2020-10-28 | 2022-05-05 | Buck Institute For Research On Aging | N-propargylglycine : inhibiteur unique de proline déshydrogénase à propriétés de mitohormèse d'amplification cérébrale pouvant atténuer des troubles neurodégénératifs |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| EP1713486A4 (fr) | 2003-12-02 | 2009-04-29 | Sheldon Leslie James | Therapie combinee pour le traitement de la demence, la depression et l'apathie |
| CN101056854B (zh) | 2004-10-13 | 2013-06-05 | Nsab神经研究瑞典公司分公司 | 合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法 |
| EP1815857A1 (fr) * | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | Composition pharmaceutique comprenant du perindopril |
| RU2470013C2 (ru) | 2007-04-12 | 2012-12-20 | НСАБ, Филиаль ау НьюроСёрч Свиден АБ, Сверийе | N-оксидные и/или ди-n-оксидные производные стабилизаторов/модуляторов рецепторов дофамина, проявляющие улучшенные профили сердечно-сосудистых побочных эффектов |
| WO2010008486A2 (fr) | 2008-06-24 | 2010-01-21 | Parkinsons Institute | Lignées cellulaires pluripotentes et procédés d’utilisation de celles-ci |
| US8384755B2 (en) | 2009-08-26 | 2013-02-26 | Intouch Technologies, Inc. | Portable remote presence robot |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (fr) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | 4-phényle-n-alkyle-pipéridines substituées destinées à prévenir le début ou à ralentir la progression de maladies neurodégénératives |
| EA201390332A1 (ru) | 2010-09-03 | 2013-08-30 | Ивакс Интернэшнл Гмбх | Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| UY34503A (es) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
| US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| JP6177875B2 (ja) | 2012-04-04 | 2017-08-09 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 併用療法のための医薬組成物 |
| IN2015DN03219A (fr) | 2012-09-27 | 2015-10-02 | Teva Pharma | |
| AU2013323133A1 (en) | 2012-09-27 | 2015-05-07 | Teva Pharmaceutical Industries Ltd. | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular Huntington's disease |
| ES2911800T3 (es) | 2014-01-22 | 2022-05-20 | Prilenia Neurotherapeutics Ltd | Formulaciones de liberación modificada de pridopidina |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (fr) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | Sel de l-tartrate de pridopidine |
| WO2016138135A1 (fr) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Modulateurs du récepteur sigma-1 pour traiter la maladie de huntington |
| US10603311B2 (en) | 2015-02-25 | 2020-03-31 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017015615A1 (fr) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Formulations à base de pridopidine et utilisation desdites formulations |
| WO2017048457A1 (fr) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combinaison de laquinimod et de pridopidine pour le traitement de la sclérose en plaques |
| WO2018039477A1 (fr) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Utilisation de la pridopidine pour le traitement du déclin fonctionnel |
| EP3503890A4 (fr) | 2016-08-24 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | Utilisation de la pridopidine pour le traitement des dystonies |
| JP2019529411A (ja) | 2016-09-15 | 2019-10-17 | プリレニア ニューロセラピューティクス リミテッド | 不安症およびうつ病の治療のためのプリドピジンの使用 |
| WO2018053275A1 (fr) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Utilisation de pridopidine pour traiter la dysautonomie familiale |
| CA3036984C (fr) | 2016-09-16 | 2023-07-18 | Prilenia Therapeutics Development Ltd. | Utilisation de la pridopidine pour le traitement du syndrome de rett |
-
2014
- 2014-06-19 CA CA2913781A patent/CA2913781C/fr active Active
- 2014-06-19 MX MX2015017307A patent/MX2015017307A/es unknown
- 2014-06-19 WO PCT/US2014/043204 patent/WO2014205229A1/fr active Application Filing
- 2014-06-19 PE PE2016002253A patent/PE20170302A1/es not_active Application Discontinuation
- 2014-06-19 BR BR112015029918A patent/BR112015029918A2/pt not_active Application Discontinuation
- 2014-06-19 PL PL14813621T patent/PL3010506T3/pl unknown
- 2014-06-19 CN CN201480035525.7A patent/CN105592848A/zh active Pending
- 2014-06-19 EP EP14813621.1A patent/EP3010506B1/fr active Active
- 2014-06-19 JP JP2016521580A patent/JP2016523862A/ja not_active Withdrawn
- 2014-06-19 HU HUE14813621A patent/HUE054783T2/hu unknown
- 2014-06-19 SG SG11201509729YA patent/SG11201509729YA/en unknown
- 2014-06-19 PE PE2015002618A patent/PE20160195A1/es not_active Application Discontinuation
- 2014-06-19 KR KR1020167001531A patent/KR102316933B1/ko active IP Right Grant
- 2014-06-19 AU AU2014281414A patent/AU2014281414A1/en not_active Abandoned
- 2014-06-19 EA EA201690069A patent/EA201690069A1/ru unknown
- 2014-06-19 ES ES14813621T patent/ES2879631T3/es active Active
- 2014-06-19 UA UAA201600462A patent/UA122999C2/uk unknown
- 2014-06-19 DK DK14813621.1T patent/DK3010506T3/da active
- 2014-06-19 US US14/309,111 patent/US10322119B2/en active Active
- 2014-06-20 TW TW103121433A patent/TW201529069A/zh unknown
- 2014-06-23 UY UY35624A patent/UY35624A/es not_active Application Discontinuation
-
2015
- 2015-11-26 IL IL242804A patent/IL242804B/en unknown
- 2015-12-02 PH PH12015502691A patent/PH12015502691A1/en unknown
- 2015-12-21 CL CL2015003690A patent/CL2015003690A1/es unknown
-
2016
- 2016-08-16 HK HK16109788.9A patent/HK1221646A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE054783T2 (hu) | 2021-09-28 |
| CN105592848A (zh) | 2016-05-18 |
| WO2014205229A1 (fr) | 2014-12-24 |
| PE20170302A1 (es) | 2017-03-31 |
| UA122999C2 (uk) | 2021-02-03 |
| UY35624A (es) | 2015-01-30 |
| EP3010506A1 (fr) | 2016-04-27 |
| DK3010506T3 (da) | 2021-07-12 |
| JP2016523862A (ja) | 2016-08-12 |
| EP3010506A4 (fr) | 2017-02-08 |
| TW201529069A (zh) | 2015-08-01 |
| PL3010506T3 (pl) | 2021-11-02 |
| PH12015502691A1 (en) | 2016-03-14 |
| IL242804B (en) | 2022-02-01 |
| WO2014205229A8 (fr) | 2015-04-09 |
| US20140378508A1 (en) | 2014-12-25 |
| US10322119B2 (en) | 2019-06-18 |
| CL2015003690A1 (es) | 2016-10-28 |
| EA201690069A1 (ru) | 2016-06-30 |
| KR102316933B1 (ko) | 2021-10-26 |
| CA2913781C (fr) | 2022-05-10 |
| PE20160195A1 (es) | 2016-05-14 |
| BR112015029918A2 (pt) | 2017-07-25 |
| AU2014281414A1 (en) | 2016-01-21 |
| CA2913781A1 (fr) | 2014-12-24 |
| KR20160055122A (ko) | 2016-05-17 |
| ES2879631T3 (es) | 2021-11-22 |
| HK1221646A1 (zh) | 2017-06-09 |
| EP3010506B1 (fr) | 2021-05-12 |
| MX2015017307A (es) | 2016-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201509729YA (en) | Use of high dose pridopidine for treating huntington's disease | |
| IL266648B (en) | A method for treating Parkinson's disease | |
| ZA201608108B (en) | Huntington's disease therapeutic compounds | |
| HK1225305A1 (zh) | 治療腦疾病的方法和組合物 | |
| EP3019523A4 (fr) | Méthodes permettant de traiter la maladie d'alzheimer et la maladie de huntington | |
| IL243976B (en) | kdm1a inhibitors for disease treatment | |
| HK1220418A1 (zh) | 治療呼吸系統疾病的方法及為此而製的製劑 | |
| EP3068905A4 (fr) | Méthodes et compositions pour traiter la maladie de huntington | |
| ZA201406209B (en) | Methods and compositions for treating huntington's disease | |
| HK1220324A1 (zh) | 用於治療血管緊張素相關疾病的方法、化合物和組合物 | |
| EP2958936A4 (fr) | Méthodes et compositions pour le traitement de la maladie de forbes-cori | |
| EP2968321A4 (fr) | Composés pour le traitement de maladies de fibrose | |
| IL239851A0 (en) | Methods and compositions for treating diseases that act to remove myelin | |
| HK1219653A1 (zh) | 治療線粒體疾病的方法 | |
| PL2959903T3 (pl) | Lek do leczenia chorób oczu | |
| EP3013834A4 (fr) | Composés benzofuranes substitués et leurs méthodes d'utilisation pour le traitement de maladies virales | |
| EP3013334A4 (fr) | Composés benzofuranes substitués et leurs méthodes d'utilisation pour le traitement de maladies virales | |
| IL243637A0 (en) | PPAR-sparing compounds for the treatment of metabolic diseases | |
| HK1218883A1 (zh) | 對神經毒劑的暴露的治療 | |
| HK1224215A1 (zh) | 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途 | |
| IL241482B (en) | A method for treating Parkinson's disease | |
| GB201310101D0 (en) | Treatment of freidreich's ataxia | |
| GB201321628D0 (en) | Treatment of disease |